Griffin Budde, Director of Oncology Sales – Cutaneous at Natera, shared a post on LinkedIn:
“‘Conclusions and Relevance: This study found that ctDNA was more accurate than MCPyV antibody testing in detecting recurrence of MCC. ctDNA appears to be a more reliable guide than the MCPyV antibody for surveillance practices and ongoing risk stratification in most patients with MCC.’
New data continuing to support the use of Signatera in merkel cell carcinoma. The NCCN guidelines have already recognized this fact.
Bottom line: Signatera is standard of care for most patients with merkel cell carcinoma.”
Title: ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma Recurrence
Authors: Manisha Thakuria, Tomoko Akaike, Ann W. Silk, Daniel S. Hippe, Peter Y. Ch’en, Rian Alam, Joshua E. Chan, Song Y. Park, Karam Khaddour, Kate B. Biese, Austin J. Jabbour, Alex Fu, Macy W. Gilmour, Ariel Finberg, Meliea W. Chiu, Hannah Kim, Nicole M. Urman, Evan Thomas Hall, Shailender Bhatia, Paul Nghiem, Lisa C. Zaba
Other articles about merkel cell carcinoma on OncoDaily.